Vanda Pharmaceuticals Inc. VNDA
We take great care to ensure that the data presented and summarized in this overview for Vanda Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VNDA
View all-
Black Rock Inc. New York, NY8.14MShares$39.8 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.57MShares$17.4 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.5MShares$17.1 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.54MShares$12.4 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.35MShares$11.5 Million0.7% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.14MShares$10.5 Million0.01% of portfolio
-
Acadian Asset Management LLC Boston, MA1.89MShares$9.23 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA1.61MShares$7.89 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V81.57MShares$7.65 Million0.01% of portfolio
-
State Street Corp Boston, MA1.25MShares$6.13 Million0.0% of portfolio
Latest Institutional Activity in VNDA
Top Purchases
Top Sells
About VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Transactions at VNDA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 13
2025
|
Stephen Ray Mitchell |
SELL
Open market or private sale
|
Direct |
7,000
-6.73%
|
$28,000
$4.59 P/Share
|
Jun 05
2025
|
Richard W Dugan |
BUY
Grant, award, or other acquisition
|
Direct |
59,225
+25.02%
|
-
|
Jun 05
2025
|
Phaedra Chrousos |
BUY
Grant, award, or other acquisition
|
Direct |
59,225
+32.44%
|
-
|
Jun 05
2025
|
Stephen Ray Mitchell |
BUY
Grant, award, or other acquisition
|
Direct |
59,225
+36.27%
|
-
|
Jun 05
2025
|
Anne Sempowski Ward |
BUY
Grant, award, or other acquisition
|
Direct |
59,225
+33.22%
|
-
|
Jun 05
2025
|
Tage Honore |
BUY
Grant, award, or other acquisition
|
Direct |
59,225
+32.42%
|
-
|
May 21
2025
|
Mihael Hristos Polymeropoulos President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+0.21%
|
$40,000
$4.4 P/Share
|
May 16
2025
|
Mihael Hristos Polymeropoulos President and CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+0.86%
|
$80,000
$4.22 P/Share
|
Mar 06
2025
|
Mihael Hristos Polymeropoulos President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+0.22%
|
$50,000
$5.02 P/Share
|
Mar 05
2025
|
Mihael Hristos Polymeropoulos President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+0.22%
|
$50,000
$5.02 P/Share
|
Mar 03
2025
|
Mihael Hristos Polymeropoulos President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+0.44%
|
$40,000
$4.7 P/Share
|
Mar 01
2025
|
Timothy Williams SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
26,941
-8.37%
|
$107,764
$4.76 P/Share
|
Mar 01
2025
|
Kevin Patrick Moran SVP, CFO & Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,941
-7.57%
|
$107,764
$4.76 P/Share
|
Mar 01
2025
|
Mihael Hristos Polymeropoulos President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
95,999
-4.06%
|
$383,996
$4.76 P/Share
|
Mar 01
2025
|
Gunther Birznieks SVP, Business Development |
SELL
Payment of exercise price or tax liability
|
Direct |
26,941
-6.14%
|
$107,764
$4.76 P/Share
|
Mar 01
2025
|
Joakim Wijkstrom SVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,520
-6.09%
|
$62,080
$4.76 P/Share
|
Feb 28
2025
|
Mihael Hristos Polymeropoulos President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+0.42%
|
$40,000
$4.76 P/Share
|
Feb 27
2025
|
Mihael Hristos Polymeropoulos President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+0.42%
|
$40,000
$4.76 P/Share
|
Feb 26
2025
|
Mihael Hristos Polymeropoulos President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+0.21%
|
$40,000
$4.77 P/Share
|
Feb 25
2025
|
Mihael Hristos Polymeropoulos President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+0.43%
|
$40,000
$4.46 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.25M shares |
---|---|
Open market or private purchase | 102K shares |
Payment of exercise price or tax liability | 192K shares |
---|---|
Open market or private sale | 14.3K shares |